Evonik has been awarded an Asia-Pacific Bioprocessing Excellence Award (ABEA) for the second year running. The company received the award for its Cell Culture Solutions portfolio in the category Best New Bioprocessing Supplier Award: Upstream Processing. Cell culture is a key growth area for Evonik’s Health Care business.
As part of the company’s life sciences division, Nutrition & Care, the Cell Culture Solutions offered by Evonik are a cornerstone to its expanding portfolio of biosolutions. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution. Nutrition & Care aims to increase its share of system solutions to 70 percent by 2032.
“It is a great honour to be recognized by the Asia-Pacific biopharma community for the second year in a row. We look forward to many more fruitful collaborations with companies in the region and look forward to exceeding their cell culture media and bioprocessing needs,” said Shirley Qi, President Southeast Asia, Australia and New Zealand/head of Nutrition & Care Asia Pacific at Evonik.
The annual Asia-Pacific Biopharma Excellence Awards (ABEA) are organized by the global biopharmaceutical B2B and marketing intelligence company IMAPAC. The awards applaud exceptional leaders, organizations and technologies that drive innovation and best practices in manufacturing in the region.
“Winning this award is a testament to the efforts of our team to serve the biopharma community. Our success further encourages us to develop more innovative solutions to solve bioprocessing challenges with our cell culture solutions portfolio,” said Spandan Mishra, Associate Director Business Development, Biopharma Solutions at Evonik Health Care for Asia Pacific.
Evonik’s extensive Cell Culture Solutions portfolio combines development expertise and manufacturing capabilities to provide highly defined and pure cell culture ingredients for use in a wide range of applications, from biopharmaceutical R&D and manufacturing to medicinal purposes.
Evonik’s solutions include the cQrex® portfolio of peptides that address specific amino acid limitations to improve stability and solubility, enabling optimal productivity and enhancing performance in biopharmaceutical cell culture media. Other specialty ingredients like carbohydrates, and the plant-derived cholesterol PhytoChol® Biopharma are also part of Evonik’s offering.
As per the press release, the health care business line at Evonik is a global innovation hub to the world’s leading pharma and biotech companies. By leveraging six decades of industry leadership, the company provides the biopharma market with high-quality cell culture solutions including amino acids, peptides, plant-based lipids and other non-animal-derived performance boosters.
